·糖尿病与肥胖、脂质代谢异常·　

调脂治疗对2型糖尿病伴脂代谢紊乱患者早期胰岛素分泌改善作用的研究

　　田景伦 周仕龙 王小红 贺奕 陈德才

　　【摘要】 目的 了解调脂治疗对T2DM伴脂代谢紊乱患者早期胰岛素分泌功能的影响。 方法 71例新诊断T2DM伴脂代谢紊乱患者作为治疗组，根据不同血脂组分接受辛伐他汀和(或)非诺贝特治疗12周;32例血脂正常的新诊断的T2DM患者作为对照(Con)组，两组均接受降糖治疗，且血糖控制均达标。分别在0周、6周和12周做OGTT，计算早期胰岛素分泌指数ΔI30/ΔG30 ，并比较其差异。 结果 治疗后两组患者的ΔI30/ΔG30 均有逐渐升高的趋势，且调脂治疗组升高程度高于Con组(P<0.05)。 结论 在一定时期内，调脂治疗对新诊断T2DM伴脂代谢紊乱患者早期胰岛素分泌功能有显著改善作用。

　　【关键词】糖尿病，2型;脂代谢障碍;降血脂药

Improvement of lipid-lowering treatment on early insulin secretion in T2DM patients accompanied with dyslipidemia TIAN Jing-lun, ZHOU Shi-long, WANG Xiao-hong, et al. Department of Endocrinology, Wenjiang People´s Hospital, Chengdu 611130, China

　　【Abstract】 Objective To investigate the effect of lipid-lowering treatment on early insulin secretion in T2DM patients accompanied with dyslipidemia. Methods Seventy-one newly diagnosed T2DM patients accompanied with dyslipidemia (treatment group) accepted simvastatin or/and fenofibrate therapy according to their different lipid fractions for 12 weeks, and the 32 newly diagnosed T2DM patients without dyslipidemia (control group) received the lipid-lowering treatment. Both groups accepted anti-hyperglycemic treatment and their glucose control was to the target. The oral glucose tolerance test (OGTT) was given in the 0, 6, and 12 weeks for calculating the early insulin secretion indexesΔI30/ΔG30 for comparison. Results After treatment, the indexesΔI30/ΔG30 of both groups had an increasing trend, and compared with the control group, the increasing degree was higher in the treatment group (P<0.05). Conclusions In a certain period of time, the lipid-lowering treatment improves the early insulin secretion of the newly diagnosed T2DM patients accompanied with dyslipidemia.

　　【Key Words】 Diabetes mellitus, type 2; Lipid metabolism disorders; Antilipemic agents